326-71-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(5-BROMO-2-THIENYL)-4,4,4-TRIFLUORO-1,3-BUTANEDIONE is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its trifluoromethyl group contributes to the development of new drugs with improved properties, such as enhanced bioavailability and potency.
Used in Agrochemical Industry:
In the agrochemical industry, 1-(5-BROMO-2-THIENYL)-4,4,4-TRIFLUORO-1,3-BUTANEDIONE serves as a crucial building block in the creation of effective agrochemicals. Its unique structure allows for the development of compounds with targeted actions, such as pest control and crop protection.
Used in Industrial Product Development:
1-(5-BROMO-2-THIENYL)-4,4,4-TRIFLUORO-1,3-BUTANEDIONE is also utilized in the development of other industrial products, where its trifluoromethyl group can enhance the performance characteristics of the final product, such as increased stability and durability.

InChI:InChI=1/C8H4BrF3O2S/c9-7-2-1-5(15-7)4(13)3-6(14)8(10,11)12/h1-2H,3H2

Upstream product

• 5370-25-2 2-Acetyl-5-bromothiophene 
• 431-47-0 trifluoroacetic acid-methyl ester 
• 383-63-1 ethyl trifluoroacetate, 

Downstream Products

• 1454288-99-3 chloromethyl 2-(5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate 
• 1454288-97-1 ethyl 2-(5-(5-(4-(hydroxymethyl)-3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate 
• 1454288-96-0 isopropyl 2-(5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate 
• 1454288-80-2 (methylthio)methyl 2-(4-bromo-5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate 
• 1454288-79-9 (methylthio)methyl 2-(5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate 
• 1454288-78-8 2-(dimethylamino)ethyl 2-(4-bromo-5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate 
• 1454288-77-7 2-(dimethylamino)ethyl 2-(5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate 
• 918328-00-4 2-(5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetic acid 
• 1454288-76-6 ethyl 2-(4-bromo-5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate 
• 1454288-75-5 ethyl 2-(5-(5-(3-(methylsulfonyl)phenyl)thiophen-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetate 

Relevant academic research and scientific papers

THIENYLHYDROXYISOXAZOLINES AND DERIVATIVES THEREOF

The present disclosure relates to the use of thienylhydroxyisoxazolines and derivatives thereof as fungicides. It also relates to new thienylhydroxyisoxazolines derivatives, their use as fungicides and compositions comprising thereof.

Liver X Receptor (LXR) partial agonists: Biaryl pyrazoles and imidazoles displaying a preference for LXRβ

A series of biaryl pyrazole and imidazole Liver X Receptor (LXR) partial agonists has been synthesized displaying LXRβ selectivity. The LXRβ selective partial agonist 18 was identified with potent induction of ATP binding transporters ABCA1 and ABCG1 in human whole blood (EC50 = 1.2 μM, 55% efficacy). In mice 18 displayed peripheral induction of ABCA1 at 3 and 10 mpk doses with no significant elevation of plasma or hepatic triglycerides at these doses, showing an improved profile compared to a full pan-agonist.

LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS

Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of dermal diseases, disorders or conditions. Also described herein are pharmaceutical compositions containg such compounds.

Thiophene based europium β-diketonate complexes: Effect of the ligand structure on the emission quantum yield

The synthesis and the molecular and photophysical characterization, together with solid state and solution structure analysis, of a series of europium complexes based on β-diketonate ligands are reported. The Eu(III) complex emission, specifically its photoluminescence quantum yield (PL-QY), can be tuned by changing ligands which finely modifies the environment of the metal ion. Steady-state and time-resolved emission spectroscopy and overall PL-QY measurements are reported and related to geometrical features observed in crystal structures of some selected compounds. Moreover, paramagnetic NMR, based on the analogous complexes with other lanthanides, are use to demonstrate that there is a significant structural reorganization upon dissolution, which justifies the observed differences in the emission properties between solid and solution states. The energy of the triplet levels of the ligands and the occurrence of nonradiative deactivation processes clearly account for the luminescence efficiencies of the complexes in the series.

Process for preparing vinyl substituted beta-diketones

A process for preparing vinyl substituted beta-diketones includes reacting a halogen-containing beta-diketone with an olefin in a reaction zone under Heck coupling reaction conditions in the presence of a catalyst, a base, and an organic phosphine to provide a vinyl substituted beta-diketone product.

Synthesis of vinyl-substituted β-diketones for polymerizable metal complexes

Polymerizable β-diketones for application to metal ion coordination have been prepared and characterized. Bromine-substituted β-diketones were synthesized under Claisen-Schmidt-type condensation conditions. Vinyl groups were substituted for the halide by

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)- 3(trifluoromethyl)-1h-pyrazol-1-yl]benzenesulfonamide (sc-58635, celecoxib)

A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC- 236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of 1i (4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-y1]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.